ALLE Stock Analysis: Allegion | NYSE
Security & Protection Services | NYSE, USA | Market Cap: 15.011m USD | 12M Return: 8.4% | IE00BFRT3W74 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 171M
EPS Trend: 98.2%
Qual. Beats: 2
Rev. Trend: 96.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Allegion plc (NYSE: ALLE) is a global provider of security products and solutions, organized into two segments: Allegion Americas and Allegion International. The company manufactures and sells a broad range of products including door controls, exit devices, locks, access control systems, and electronic security products, as well as related services and software such as access control, workforce management, inspection, maintenance, and design and installation offerings. It serves end-users across commercial, institutional, and residential markets-including education, healthcare, government, hospitality, retail, and office facilities-under brands such as Schlage, Von Duprin, LCN, CISA, SimonsVoss, and Interflex. Allegion distributes its products through specialty distribution, e-commerce, wholesalers, and retail channels like do-it-yourself home improvement centers. The company was incorporated in 2013 and is headquartered in Dublin, Ireland, operating within the Industrials sectors Building Products sub-industry. As a pure-play security and access solutions provider, Allegion generates a meaningful share of revenue from recurring aftermarket services and software subscriptions, which tend to provide more stable cash flows than the sale of physical hardware tied to new construction cycles.
- Non-residential construction trends drive Americas segment revenue
- Electronic security and access control margins expand
- European commercial weakness pressures International segment growth
| Net Income: 658.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.38 > 1.0 |
| NWC/Revenue: 16.85% < 20% (prev 24.48%; Δ -7.63% < -1%) |
| CFO/TA 0.15 > 3% & CFO 781.7m > Net Income 658.6m |
| Net Debt (1.71b) to EBITDA (1.04b): 1.65 < 3 |
| Current Ratio: 1.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.0m) vs 12m ago -0.46% < -2% |
| Gross Margin: 44.80% > 18% (prev 44.83%; Δ -0.03% > 0.5%) |
| Asset Turnover: 83.47% > 50% (prev 78.88%; Δ 4.59% > 0%) |
| Interest Coverage Ratio: 8.87 > 6 (EBIT TTM 892.9m / Interest Expense TTM 100.7m) |
| A: 0.13 (Total Current Assets 1.50b - Total Current Liabilities 777.3m) / Total Assets 5.36b |
| B: 0.44 (Retained Earnings 2.35b / Total Assets 5.36b) |
| C: 0.17 (EBIT TTM 892.9m / Avg Total Assets 5.14b) |
| D: 0.65 (Book Value of Equity 2.12b / Total Liabilities 3.24b) |
| Altman-Z'' = 4.17 = AA |
| DSRI: 1.06 (Receivables 559.7m/477.4m, Revenue 4.29b/3.88b) |
| GMI: 1.00 (GM 44.83% / 44.80%) |
| AQI: 1.11 (AQ_t 0.64 / AQ_t-1 0.58) |
| SGI: 1.11 (Revenue 4.29b / 3.88b) |
| TATA: -0.02 (NI 658.6m - CFO 781.7m) / TA 5.36b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at USD 180.66 with a total of 1,565,815 shares traded. Over the past week, the price has changed by +13.62%, over one month by +16.27%, over three months by +12.45% and over the past year by +8.42%.
Current recommended Stop Loss: 175.30 (which is 3% or 1.2 ATR below the current price).
Allegion has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ALLE.
- StrongBuy: 5
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 182 | 0.7% |
P/E Trailing = 21.9552
P/E Forward = 15.9236
P/S = 3.5002
P/B = 6.1849
P/EG = 2.0408
Revenue TTM = 4.29b USD
EBIT TTM = 892.9m USD
EBITDA TTM = 1.04b USD
Long Term Debt = 2.03b USD (from longTermDebt, last quarter)
Short Term Debt = 200k USD (from shortTermDebt, last quarter)
Debt = 2.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.71b USD (calculated: Debt 2.03b - CCE 320.6m)
Enterprise Value = 16.7b USD (15.0b + Debt 2.03b - CCE 320.6m)
Interest Coverage Ratio = 8.87 (Ebit TTM 892.9m / Interest Expense TTM 100.7m)
EV/FCF = 24.52x (Enterprise Value 16.7b / FCF TTM 681.9m)
FCF Yield = 4.08% (FCF TTM 681.9m / Enterprise Value 16.7b)
FCF Margin = 15.90% (FCF TTM 681.9m / Revenue TTM 4.29b)
Net Margin = 15.36% (Net Income TTM 658.6m / Revenue TTM 4.29b)
Gross Margin = 44.80% ((Revenue TTM 4.29b - Cost of Revenue TTM 2.37b) / Revenue TTM)
Gross Margin QoQ = 44.94% (prev 43.97%)
Tobins Q-Ratio = 3.12 (Enterprise Value 16.7b / Total Assets 5.36b)
Interest Expense / Debt = 4.96% (Interest Expense 100.7m / Debt 2.03b)
Taxrate = 16.86% (133.6m / 792.2m)
NOPAT = 742.3m (EBIT 892.9m * (1 - 16.86%))
Current Ratio = 1.93 (Total Current Assets 1.50b / Total Current Liabilities 777.3m)
Debt / Equity = 0.96 (Debt 2.03b / totalStockholderEquity, last quarter 2.12b)
Debt / EBITDA = 1.65 (Net Debt 1.71b / EBITDA 1.04b)
Debt / FCF = 2.51 (Net Debt 1.71b / FCF TTM 681.9m)
Total Stockholder Equity = 2.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.82% (Net Income 658.6m / Total Assets 5.36b)
RoE = 31.99% (Net Income TTM 658.6m / Total Stockholder Equity 2.06b)
RoCE = 21.83% (EBIT 892.9m / Capital Employed (Equity 2.06b + L.T.Debt 2.03b))
RoIC = 16.99% (NOPAT 742.3m / Invested Capital 4.37b)
WACC = 6.60% (E(15.0b)/V(17.0b) * Re(6.94%) + D(2.03b)/V(17.0b) * Rd(4.96%) * (1-Tc(0.17)))
Discount Rate = 6.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.10 | Cagr: -1.07%
[DCF] Terminal Value 75.22% ; FCFF base≈686.3m ; Y1≈680.0m ; Y5≈701.4m
[DCF] Fair Price = 108.5 (EV 10.9b - Net Debt 1.71b = Equity 9.23b / Shares 85.0m; r=8.35% [WACC [floored]]; 5y FCF grow -1.59% → 2.50% )
EPS Correlation: 98.21 | EPS CAGR: 8.57% | SUE: 1.02 | # QB: 2
Revenue Correlation: 96.84 | Revenue CAGR: 6.34% | SUE: 2.94 | # QB: 1
EPS current Quarter (2027-03-31): EPS=2.16 | Chg30d=+1.92% | Revisions=+57% | Analysts=7
EPS current Year (2026-12-31): EPS=9.11 | Chg30d=+1.74% | Revisions=+29% | GrowthEPS=+11.9% | GrowthRev=+10.0%
EPS next Year (2027-12-31): EPS=9.95 | Chg30d=+1.84% | Revisions=+0% | GrowthEPS=+9.2% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +40% (up=9, down=3)